Case-control study shows reduced RSV-related hospitalizations in high-risk infants, suggesting a policy change in prevention strategies.
This case-control study of Chile's nationwide nirsevimab immunization program found that RSV-related LRTI hospitalizations among infants at higher risk of severe disease were substantially reduced. These findings support replacing targeted palivizumab prophylaxis with a broader, universal nirsevimab strategy as part of RSV prevention policy.
No takes yet. Share an insight, caveat, or question.
Sauré et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: